China’s Research on COVID-19 Video Report: Vaccine Development

来源：中华预防医学会微平台

As of June 18, COVID-19 has hit over 210 countries and regions, affected more than seven billion people around the world and claimed over 440,000 precious lives. The virus does not respect borders. Nor is race or nationality relevant in the face of the disease.

In order to support Open Science advocated by UNESCO, and to share China‘s knowledge and practices in fighting COVID-19, China Centre for International Science and Technology Exchange (CISTE) has produced a series of videos titled “China's Research on COVID-19” in cooperation with CAST UN Consultative Committee on Life Sciences and Human Health (CCLH) and CAST UN Consultative Committee on Information Technology (CCIT).

No.2: Vaccine Development

Vaccines are the most critical weapon to defeat the COVID-19. Since the outbreak, China has been simultaneously developing vaccines via five different technical pathways, including inactivated, nucleic-acid, recombinant protein-based, adenovirus vectored and influenza virus vectored vaccines.

As of June 2, among the 3153 vaccine projects registered with the World Health Organization, China has registered 788 projects, of which 11 were jointly registered by researchers from China and the countries else. These projects are carried out in 80 cities in China, including Beijing, Shanghai and Wuhan.

China has contributed 7 projects among the 123 candidate vaccines in preclinical evaluation,  5 among the 10 candidate vaccines, including one Adenovirus Type 5 Vector vaccine, three inactivated vaccines and one inactivated + alum.

In the article published in Science titled “Development of an inactivated vaccine candidate for SARS-CoV-2,” Professor GAO Qiang’s team stated that “an  inactivated SARS-CoV-2 virus vaccine candidate was developed, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates and these antibodies neutralized 10 representative SARS-CoV-2 strains from 5 countries”.

In the article published in The Lancet titled “Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial” Professor ZHU Fengcai and his colleagues stated that “ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination,” indicating that the vaccine can induce an immune response in human body, triggering an antibody response specific to the SARS-CoV-2.

微信名称

中国国际科技交流中心

长按二维码关注我们！